Clinical Trials on The Value of Procalcitonin in Patients With Suspected Candidemia in Hong Kong

Total 9 results

Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Agitation in Patients With Dementia of the Alzheimer's Type

United States, Estonia, Germany, Poland, Portugal, Puerto Rico
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Agitation in Patients With Dementia of the Alzheimer's Type

United States, Bulgaria, Denmark, Estonia, Greece, Poland, Portugal, Puerto Rico, United Kingdom, Germany, Ukraine
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Agitation in Patients With Dementia of the Alzheimer's Type

United States, Belgium, Canada, Chile, Colombia, Croatia, Hungary, Mexico, Netherlands, Slovakia, Slovenia, Spain, Ireland
Otsuka Pharmaceutical Development & Commercialization...

Completed

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Agitation in Patients With Dementia of the Alzheimer's Type

Spain, United States, Italy, United Kingdom, Hungary, France, Poland, Australia, Bulgaria, Czechia, South Africa
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Agitation in Patients With Dementia of the Alzheimer's Type

United States, Spain, Hungary, Italy, Canada, Czechia, South Africa, Bulgaria, France, Poland
Axsome Therapeutics, Inc.

Completed

Addressing Dementia Via Agitation-Centered Evaluation (ADVANCE)

Alzheimer Disease | Agitation in Patients With Dementia of the Alzheimer's Type | Agitation,Psychomotor

United States, Australia
Axsome Therapeutics, Inc.

Recruiting

A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation (ADVANCE-2)

Alzheimer Disease | Agitation | Agitation in Patients With Dementia of the Alzheimer's Type

United States, Puerto Rico
Axsome Therapeutics, Inc.

Enrolling by invitation

A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation

Alzheimer Disease | Agitation in Patients With Dementia of the Alzheimer's Type | Agitation, Psychomotor

United States, Canada
National Cancer Institute (NCI)

Completed

Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy (MAESTRO HN)

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Salivary Gland Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Nasopharyngeal Keratinizing Squamous... and other conditions

United States, China

Clinical Trials on The Value of Procalcitonin in Patients With Suspected Candidemia in Hong Kong

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations